Cancer Epidemiology Services

Select textsizemediumlargelarger

Meaningful Use Stage 2(MU2) – Cancer Reporting

Please view the NJDOH’s webpage on Cancer Reporting for MU2

Population-based cancer surveillance is critical for cancer control activities aimed at reducing the morbidity and mortality of cancer. Cancer reporting from ambulatory providers to state cancer registries is a new public health objective for Meaningful Use. Data collection from providers presents new challenges since the infrastructure for reporting is less mature than it is in hospitals. Certified EHR Technology can address this barrier by identifying reportable cancer cases and treatments to the provider and facilitating electronic reporting either automatically or upon verification by the provider.

Onboarding Process

The onboarding process begins with registration of intent.  For more information about the NJSCR’s readiness, registration, and onboarding please see Frequently Asked Questions (FAQs).

Cancer Reporting Registration for physicians (and other ambulatory providers) is now open. If you have any questions about cancer reporting to the NJSCR using a certified EHR or registration please send an email to

Helpful Resources for Certified EHR Reporting

Note: All providers, including hospitals and physicians, regardless of Meaningful Use, are required to report cancers to the NJSCR within 6 months of diagnosis as specified in N.J.A.C. 8:57A. Providers who do not diagnose or treat cancer, and are not required to report diseases and conditions to the NJ State Cancer Registry per N.J.A.C. 8:57A, should not register for MU2 reporting on this site. NJDOH does not provide any additional documentation for attestation or exclusions/exemptions.